Highlights

  • Analysts maintain a Buy rating on McKesson Corp., with a consensus target of USD 957.17.
  • The company’s long-term growth expectations are approximately 14.1%, despite regulatory challenges.
  • Recent quarterly performance and revenue trends underpin market expectations for potential gains.

McKesson Corp (NYSE:MCK), a major U.S.-based healthcare distribution company, continues to receive a positive reception from market analysts. According to EODHD/Others data as of 11Feb 2026, Current consensus data reflects a Buy rating, with a target price of USD 957.17, implying an estimated upside of roughly 2.35% from current levels.

The brokerage community’s outlook is based on McKesson’s ongoing operations in pharmaceutical distribution and its ability to maintain consistent revenue streams. Analysts cite the company’s long-term growth trajectory, projected at approximately 14.1%, as a key factor influencing recommendations. This is occurring in the context of a healthcare market that faces regulatory scrutiny and supply chain constraints, factors analysts are monitoring closely.

Recent Financial Performance
McKesson’s most recent quarterly performance has shown steady revenue trends, contributing to analyst expectations. While daily trading for February 10 showed no change in the share price at USD 935.21, the stock has experienced notable movement over different time frames, including a 13.27% gain over the past month and a 39.01% increase over the past six months. Year-to-date performance shows a 13.57% rise, with annual gains at 53.21%.

These figures reflect the market’s response to McKesson’s operational stability and its ability to navigate challenges in the distribution of pharmaceuticals. Despite broader industry pressures, revenue growth and guidance updates have been a reference point for market participants assessing the stock’s potential trajectory.

Growth Prospects and Long-Term View
The consensus among analysts highlights McKesson’s capacity to sustain long-term growth. The projected growth rate of approximately 14.1% is seen as a measure of the company’s ability to maintain its position in a complex healthcare distribution environment. Market participants are weighing these projections alongside the current regulatory landscape and supply chain dynamics, emphasizing the cautious optimism underpinning brokerage ratings.

Analysts note that while potential upside from current levels appears moderate at roughly 2.35%, the company’s consistent performance and strategic positioning in the pharmaceutical distribution sector remain factors of interest.

With brokerage assessments showing a positive stance, McKesson Corp is navigating an environment marked by regulatory oversight, supply chain considerations, and consistent revenue performance. Market participants are monitoring quarterly execution and long-term growth trends as the company works within its operational and strategic framework.

FAQs

Q1. What is the current analyst rating for McKesson Corp?
Analysts maintain a Buy rating on McKesson, with a consensus target price of USD 957.17.

Q2. What are the long-term growth expectations?
McKesson’s long-term growth rate is projected at approximately 14.1%, according to analysts.

Q3. How did McKesson perform recently?
The stock price was USD 935.21 on February 10, with a 13.27% gain over the past month and a 39.01% increase over six months.